Core Viewpoint - HSBC has upgraded Nike's stock rating to 'Buy' from 'Hold' and increased the price target to $80 from $60, citing evidence of sales recovery and margin improvement [1] Group 1: Upgrade Factors - The new management team under CEO Elliott Hill is focusing on quality over quick fixes, which is expected to benefit Nike in the long term [2] - The repositioning of the digital channel as a full-price channel is highlighted as a positive change [2] - After two quarters of inventory clean-up, the brand assortment is expected to be current and exciting, despite challenges with the Dunk line [2] Group 2: Financial Performance - Nike's stock surged 12% in after-hours trading following the earnings call, despite mixed results [3] - The company reported earnings per share of 14 cents, slightly above estimates, while sales declined 12% to $11.1 billion [3] - Net income fell 86% to $211 million from $1.5 billion in the previous year [3] Group 3: Challenges and Outlook - Nike faces headwinds from new tariffs on Chinese goods, expecting a $1 billion impact in fiscal 2026 [4] - Currently, 16% of Nike's supply chain runs through China, with plans to reduce this to high single digits by next summer as part of the 'Win Now' strategy [4] - HSBC's price target of $80 indicates a 28% upside from Nike's current trading price of $62.54, despite a year-to-date decline of 17.35% prior to the recent rally [4]

Core Viewpoint - Abbott Laboratories is experiencing strong sales recovery in its Nutrition business, particularly driven by Ensure, and is well-positioned for growth in emerging markets and its Diabetes Care segment through the FreeStyle Libre system [1][5][6] Group 1: Sales Performance - Abbott's shares have increased by 19.6% over the past year, outperforming the industry growth of 9.1% and the S&P 500's increase of 5.4% [2] - In the fourth quarter of 2024, Abbott's Diabetes Care sales exceeded $1.8 billion, reflecting a 23% growth, while full-year sales reached approximately $6.5 billion, up 22% from 2023 [7] - The Nutrition business reported 7.1% organic growth in the fourth quarter of 2024, with Adult Nutrition growing by 11.4% [9] Group 2: Business Segments - The EPD (Established Pharmaceutical Division) is set for sustainable growth, with a five-year compound annual growth rate (CAGR) of 8% [3] - EPD sales in the fourth quarter of 2024 increased by 8.5% organically, with balanced growth across various therapeutic areas [4] - The FreeStyle Libre system has achieved global leadership in continuous glucose monitoring for both Type 1 and Type 2 diabetes users [5] Group 3: Market Dynamics - Abbott has gained momentum in the Diabetes Care segment with recent FDA approvals for new over-the-counter CGM systems, expanding its market reach [6] - The Nutrition business is expanding due to strong global demand for adult nutrition products, despite some softness in pediatric product markets [8] - Foreign exchange fluctuations have negatively impacted Abbott's sales, with a 1.4% unfavorable year-over-year effect noted in the fourth quarter of 2024 [10] Group 4: Financial Estimates - The Zacks Consensus Estimate for Abbott's 2025 earnings per share remains at $5.15, while revenues are projected to rise by 5.7% to $44.35 billion [11]